flâneur

Home | Substack

substack.com · 1,736 words · saved by 1 readers

There is tons of stuff out there on the interweb about Pharmacy Benefit Managers (PBM). A lot is happening in the policy space right now, and it’s worth capturing the state of affairs. Part 1 of this series covers the market players and some industry jargon. Part 2 of the series covers the history of how PBMs became powerful and their interactions with other market players. Part 3 of the series covers the ever-evolving business model, the systemic problems, and emerging developments on the regulatory and strategy front. $350 billion are spent on prescription drugs, accounting for over 8% of the $4 trillion spent on healthcare annually in the US. Americans pay more than double the average OECD country per capita (OECD is a forum of 37 high-income, developed countries). If more people knew about this un-legislated “tax” we would have a modern-day Boston Tea Party. PBMs first emerged to manage basic pharmacy claims. Over time they evolved into complex organizations that offer soup to nuts

I have launched a podcast! You can also listen to this post on Spotify Warning: This series of posts is long, like a CVS receipt. There is tons of stuff out there on the interweb about Pharmacy Benefit Managers (PBM). A lot is happening in the policy space right now, and it’s worth capturing the state of affairs. Part 1 of this series covers the market players and some industry jargon. Part 2 of the series covers the history of how PBMs became powerful and their interactions with other market players. Part 3 of the series covers the ever-evolving business model, the systemic problems, and…

related reading